[Treatment with gonadotropin-releasing hormone analogs (GnRHa) in childhood and adolescence].
Key Findings
- Triptorelin effectively suppresses LH, FSH, estradiol, and testosterone, halting secondary sexual development.
- It’s considered safe and is the standard treatment for central precocious puberty in Argentina.
- Beyond early puberty, it’s also used in transgender adolescents, cancer patients, short‑stature cases, and some neurodevelopmental disorders.
Practical Outcomes
- While the data confirm triptorelin’s efficacy and safety in pediatric hormone control, it offers limited direct guidance for adult longevity or performance hacks. Biohackers might note the hormone‑suppressing effects, but any off‑label use should be approached with caution and medical supervision.
Summary
The paper reviews how the hormone blocker triptorelin, a GnRH analog, is used to pause puberty by lowering sex hormones, and notes it’s safe and effective for kids with early puberty, some growth issues, and certain medical conditions.
Abstract
For several decades, gonadotropin releasing hormone analogs (GnRHa) are the medical treatment selected for central precocious puberty (CPP) in girls and boys. They generate an inhibition of the hypothalamus-pituitary-gonadal axis decreasing LH, FSH, estradiol and testosterone secretion and, in this way, they produce a regression of secondary sexual characters under treatment. In the last years, these analogs are also used in trans adolescents, in adolescents and young adults with oncological diseases, in some very particular situations in children with short stature and in patients with neurodevelopmental disorders. In Argentina the most commonly used formulations are triptorelin and leuprolide acetate depot forms. These analogs have proven both their efficacy and their safety. The aim of this paper is to review and update about the use of GnRHa in children and adolescents.
Study Information
pubmed
2021
2021-12-21T00:00:00.000Z
10.5546/aap.2022.s1
32